Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1347-1350

  Charpentier, Charlotte ^a   Gody, Jean Chrysostome ^b   Tisserand, Pascaline ^a   Matta, Mathieu ^a   Péré, Hélène ^a   Fournier, Julien ^a   Mbitikon, Olivia ^a   Bélec, Laurent ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b Hôpital de l'Amitié   (Central African Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIRETROVIRUS AGENT; ASPARAGINE; CYSTEINE; GLYCINE; LYSINE; NEVIRAPINE; TYROSINE;

ANTIVIRAL RESISTANCE; ARTICLE; CENTRAL AFRICAN REPUBLIC; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; DOSE RESPONSE; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; VIRUS GENE; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CENTRAL AFRICAN REPUBLIC; CHILD; CHILD, PRESCHOOL; DNA FINGERPRINTING; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MUTATION; NEVIRAPINE; POPULATION SURVEILLANCE; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 83455200006     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1896     Document Type: Article

References (14)

1. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.
2. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl.2:25-36. (Pubitemid 352019087)
3. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-2169. (Pubitemid 41669007)
4. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42:610-613. (Pubitemid 44162432)
5. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision (Accessed 3 January 2011.) Available from http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf
6. van Zyl GU, Cotton MF, Claassen M, Abrahams C, Preiser W. Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa. Pediatr Infect Dis J 2010; 29:370-371.
7. Ferreira FG, Pinto JA, Kakehasi FM, et al. Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically Infected children in Belo Horizonte, Brazil. AIDS Res Hum Retroviruses 2010; 26:229-232.
8. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access 2006. (Accessed 17 July 2011.) Available from http://www.who.int/hiv/pub/ guidelines/pmtct/en/index.html
9. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4:e4724.
10. Aghokeng AF, Mpoudi-Ngole E, Chia JE, Edoul EM, Delaporte E, Peeters M. High failure rate of ViroSeqTM HIV-1 genotyping system for drug resistance testing in Cameroon, a country of broad HIV-1 genetic diversity. J Clin Microbiol 2011; 49:1635-1641.
11. Myatt M, Bennett DE. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 2008; 13 Suppl 2:37-48. (Pubitemid 352019088)
12. Arrivé E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021. (Pubitemid 350018545)
13. Church JD, Mwatha A, Bagenda D, et al. In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. AIDS Res Hum Retroviruses 2009; 25:673-677.
14. Gody JC, Charpentier C, Mbitikon O, et al. High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. J Acquir Immune Defic Syndr 2008; 49:566-569.